miR-877-5p as a Potential Link between Triple-Negative Breast Cancer Development and Metabolic Syndrome
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316758 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Juana Moro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires 1428, A…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Metabolic Syndrome, MicroRNAs, Circulating MicroRNA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina) and Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT, Argentina), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina), Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT, Argentina).
Abstract (Originalsprache)
Metabolic syndrome (MS) is a risk factor for breast cancer (BC) that increases its aggressiveness and metastasis. The prevalence of MS is higher in triple-negative breast cancer (TNBC), which is the molecular subtype with the worst prognosis. The molecular mechanisms underlying this association have not been fully elucidated. MiRNAs are small, non-coding RNAs that regulate gene expression. Aberrant expression of miRNAs in both tissues and fluids are linked to several pathologies. The aim of this work was to identify circulating miRNAs in patients with alterations associated with MS (AAMS) that also impact on BC. Using microarray technology, we detected 23 miRNAs altered in the plasma of women with AAMS that modulate processes linked to cancer. We found that let-7b-5p and miR-28-3p were decreased in plasma from patients with AAMS and also in BC tumors, while miR-877-5p was increased. Interestingly, miR-877-5p expression was associated with lower patient survival, and its expression was higher in PAM50 basal-like BC tumors compared to the other molecular subtypes. Analyses from public databases revealed that miR-877-5p was also increased in plasma from BC patients compared to plasma from healthy donors. We identified IGF2 and TIMP3 as validated target genes of miR-877-5p whose expression was decreased in BC tissue and moreover, was negatively correlated with the levels of this miRNA in the tumors. Finally, a miRNA inhibitor against miR-877-5p diminished viability and tumor growth of the TNBC model 4T1. These results reveal that miR-877-5p inhibition could be a therapeutic option for the treatment of TNBC. Further studies are needed to investigate the role of this miRNA in TNBC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires 1428, Argentina.
- Centro de Investigaciones Inmunológicas Básicas y Aplicadas (CINIBA), Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Buenos Aires 1900, Argentina.
- Laboratorio de Inmunobiología del Cáncer, Instituto de Investigaciones en Medicina Traslacional (IIMT), Universidad Austral, CONICET, Buenos Aires 1629, Argentina.
- Hospital Militar Central, CABA, Buenos Aires 1426, Argentina.
ORCID-Profile: Ezequiel Lacunza, Adriana De Siervi
Förderung
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina) and Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT, Argentina)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina)
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT, Argentina)
Zitieren
APA
Moro, J., Grinpelc, A., Farré, P. L., Duca, R. B., Lacunza, E., Graña, K. D., Scalise, G. D., Dalton, G. N., Massillo, C., Piccioni, F., Dimase, F., Batagelj, E., De Siervi, A., & De Luca, P. (2023). miR-877-5p as a Potential Link between Triple-Negative Breast Cancer Development and Metabolic Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316758
Vancouver
Moro J, Grinpelc A, Farré PL, Duca RB, Lacunza E, Graña KD, et al. miR-877-5p as a Potential Link between Triple-Negative Breast Cancer Development and Metabolic Syndrome. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316758
BibTeX
@article{Moro2023,
author = {Moro, Juana and Grinpelc, Agustina and Farré, Paula Lucía and Duca, Rocío Belén and Lacunza, Ezequiel and Graña, Karen Daniela and Scalise, Georgina Daniela and Dalton, Guillermo Nicolás and Massillo, Cintia and Piccioni, Flavia and Dimase, Federico and Batagelj, Emilio and De Siervi, Adriana and De Luca, Paola},
title = {miR-877-5p as a Potential Link between Triple-Negative Breast Cancer Development and Metabolic Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316758}
}
EUVIMED